Scholar Rock Holding Corporation

What they do

Scholar Rock discovers and develops monoclonal antibodies that target latent growth factors, focusing on rare neuromuscular diseases. Its lead candidate, apitegromab, is a fully human antibody that inhibits myostatin activation to increase muscle mass and strength, in development for SMA and FSHD. The company also has a subcutaneous formulation of apitegromab and a preclinical/clinical pipeline including SRK-439, SRK-181, SRK-373, and SRK-256.

Revenue drivers

• Apitegromab (IV) for SMA — No commercial revenue yet; BLA resubmitted in March 2026 with PDUFA date September 30, 2026. If approved, this would be the first regulatory approval of a myostatin inhibitor.
• Apitegromab subcutaneous formulation — Phase 1 healthy volunteer study completed; ongoing development with planned FDA and EMA regulatory engagements. Intended to offer a more convenient administration route.
• Other pipeline programs (SRK-439, SRK-181, SRK-373, SRK-256) — SRK-439 is in Phase 1 with topline data expected 2H 2026; SRK-181 is Phase 2-ready but seeking partnerships. No revenue contribution currently.

Recent performance

For the year ended December 31, 2025, Scholar Rock reported zero revenue and a net loss of $378.0 million, with diluted EPS of -$3.29 and operating cash flow of -$300.0 million. As of June 30, 2026, the company had cash and equivalents of $437.1 million (including $63 million from ATM proceeds) and total assets of $523.5 million; long-term debt stood at $196.2 million. The second quarter 2026 earnings release highlighted continued FDA review of the apitegromab BLA and the initiation of the Phase 2 FORGE study in FSHD.

Strategy

Scholar Rock is focused on becoming a commercial-stage biotech by launching apitegromab in the U.S. upon approval, with a commercial team already active in the SMA community. The company is advancing a second fill-finish facility to provide redundancy for manufacturing. Beyond SMA, it has initiated the Phase 2 FORGE study in FSHD and is exploring additional indications. For non-core programs (SRK-181, SRK-373, SRK-256, and GLP-1 combinations), it is actively seeking partnerships. Regulatory strategy includes engaging with EMA on the MAA and potentially adding the second fill-finish facility to that application.

Risks

• FDA approval delay or non-approval of apitegromab — The company received a CRL in September 2025 due to cGMP deficiencies at a third-party fill-finish facility; the BLA was resubmitted in March 2026 and approval is not guaranteed by the September 30, 2026 PDUFA date.
• Manufacturing and facility issues — The Catalent Indiana facility (part of Novo Nordisk) received a Form 483 and a Warning Letter; its FDA inspection classification is pending, which could affect both FDA and EMA approvals.
• Commercial execution risk — If approved, Scholar Rock will need to build and execute a commercial launch for SMA, a rare disease market, competing with established therapies; market acceptance is uncertain.
• Clinical and development setbacks — Phase 2 and Phase 1 trials may fail to meet endpoints, and top-line data may not predict final results; delays in enrollment or regulatory hurdles could push back milestones.

Outlook

Management expects 2026 to be transformative, with potential FDA approval of apitegromab and a U.S. commercial launch imminent upon approval. They anticipate regulatory approvals in both the U.S. and Europe in 2026, though EMA timing depends on inspection classification and potential addition of a second facility. Cash of $437.1 million as of June 30, 2026 is expected to fund operations, and the company is preparing for commercial supply with ample inventory from the second fill-finish facility.